Exposed: 10 CENT Crypto to Explode April 20th?

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Jonathan Freve Biography and Net Worth

CFO of Galecto

Jon Freve brings more than 20 years of financial experience in the biotechnology sector. Prior to joining Galecto, Jon served as CFO and Treasurer of Spring Bank Pharmaceuticals, a publicly listed clinical stage biotechnology company, and before that, as Sr. Director of Finance at Santaris Pharma. He began his career at the Financial Accounting Standards Board (FASB) and PricewaterhouseCoopers, where he worked in audit and transaction services. Jon has worked on several successful initial public offerings, secondary offerings, mergers and acquisitions and is a certified public accountant. He holds a Bachelor’s degree in Business Administration from the University of Massachusetts Amherst.

What is Jonathan Freve's net worth?: The estimated net worth of Jonathan Freve is at least $1,390.20 as of June 23rd, 2021. Mr. Freve owns 2,000 shares of Galecto stock worth more than $1,390 as of April 26th. This net worth evaluation does not reflect any other investments that Mr. Freve may own. Additionally, Mr. Freve receives a salary of $604,930.00 as CFO at Galecto. Learn More about Jonathan Freve's net worth.
How old is Jonathan Freve?: Mr. Freve is currently 46 years old. There are 2 older executives and no younger executives at Galecto. The oldest executive at Galecto is Dr. Hans T. Schambye M.D., Ph.D., Co-Founder, President, CEO & Director, who is 58 years old. Learn More on Jonathan Freve's age.
What is Jonathan Freve's salary?: As the CFO of Galecto, Inc., Mr. Freve earns $604,930.00 per year. The highest earning executive at Galecto is Dr. Hans T. Schambye M.D., Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $700,130.00 per year. Learn More on Jonathan Freve's salary.
How do I contact Jonathan Freve?: The corporate mailing address for Mr. Freve and other Galecto executives is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. Galecto can also be reached via phone at 45-7070-5210. Learn More on Jonathan Freve's contact information.
Has Jonathan Freve been buying or selling shares of Galecto?: Jonathan Freve has not been actively trading shares of Galecto in the last ninety days. Most recently, on Friday, December 3rd, Jonathan Freve bought 4,000 shares of Galecto stock. The stock was acquired at an average cost of $2.49 per share, with a total value of $9,960.00. Learn More on Jonathan Freve's trading history.
Who are Galecto's active insiders?: Galecto's insider roster includes Jonathan Freve (CFO), Bertil Lindmark (Insider), Hans Schambye (CEO), and Garrett Winslow (General Counsel). Learn More on Galecto's active insiders.
Are insiders buying or selling shares of Galecto?: In the last year, insiders at the sold shares 3 times. They sold a total of 443,300 shares worth more than $1,209,944.00. The most recent insider tranaction occured on July, 31st when Major Shareholder Orbimed Advisors Llc sold 209,400 shares worth more than $628,200.00. Insiders at Galecto own 12.1% of the company. Learn More about insider trades at Galecto.
Information on this page was last updated on 7/31/2023.

Jonathan Freve Insider Trading History at Galecto

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/3/2021	Buy	4,000	$2.49	$9,960.00
11/8/2021	Buy	3,000	$3.40	$10,200.00
8/18/2021	Buy	3,000	$3.92	$11,760.00
6/23/2021	Buy	2,000	$4.74	$9,480.00	2,000

Jonathan Freve Buying and Selling Activity at Galecto

Galecto Company Overview

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Today's Range

Now: $0.70

$0.66

$0.71

50 Day Range

MA: $0.74

$0.66

$0.89

2 Week Range

Now: $0.70

$0.50

$3.70

Volume

119,427 shs

Average Volume

224,941 shs

Market Capitalization

$18.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Click For My #1 FREE Crypto for 2024

Jonathan Freve Biography and Net Worth

What is Jonathan Freve's net worth?

How old is Jonathan Freve?

What is Jonathan Freve's salary?

How do I contact Jonathan Freve?

Has Jonathan Freve been buying or selling shares of Galecto?

Who are Galecto's active insiders?

Are insiders buying or selling shares of Galecto?